We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Denali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss
Read MoreHide Full Article
Denali Therapeutics’ (DNLI - Free Report) shares rose 4.4% on Nov 5, after the company reported third-quarter results and positive pipeline updates.
Denali incurred a loss of 69 cents per share for third-quarter 2021, wider than the Zacks Consensus Estimate of a loss of 51 cents and the year-ago loss of 54 cents, primarily due to higher expenses and lower revenues.
Collaboration revenues came in at $5.3 million for the reported quarter, missing the Zacks Consensus Estimate of $25 million and declining from $9.4 million in the year-ago period. The year-over-year decline was primarily owing to a decrease in revenues from the company’s collaboration with Takeda (TAK - Free Report) , driven by a decrease in costs incurred in the partnered programs.
In the year so far, Denali’s shares have declined 34.3% compared with the industry’s 12.4% decline.
Image Source: Zacks Investment Research
Quarter in Detail
Research and development expenses were $71.6 million for the quarter under review compared with $53.7 million in the year-ago period, primarily driven by an increase in personnel-related costs.
General and administrative expenses were $19.3 million, up from $15.8 million in the year-ago quarter due to an increase in personnel-related costs, including stock-based compensation, primarily due to higher headcount and additional equity award grants.
Cash, cash equivalents and marketable securities were approximately $1.4 billion as of Sep 30, 2021.
Recent Updates
In September, the company announced that it initiated dosing participants in a phase Ib study with DNL343, its brain-penetrant small molecule activator of EIF2B, in amyotrophic lateral sclerosis (ALS) patients. Denali initiated the study on the basis of positive data from preclinical and phase I studies, wherein DNL343 achieved safety and biomarker goals.
Denali also announced additional positive interim data from a phase I/II study evaluating ETV:IDS (DNL310), an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system and peripheral manifestations of Hunter syndrome in July 2021. Based on this data, the company will initiate a pivotal phase II/III study in first-half 2022 and is currently enrolling patients in Cohort C of the phase I/II study to further evaluate the clinical endpoints of the study in patients aged below four years in Hunter syndrome.
Last month, Denali announced that partner Sanofi (SNY - Free Report) plans to initiate a phase II HIMALAYA study in first-quarter 2022 to evaluate the efficacy and safety of RIPK1 inhibitor, DNL788, in adult patients having ALS.
The company also plans to initiate late-stage clinical development of its LRRK2 inhibitor, DNL151, in Parkinson's disease. DNL151 is being developed in collaboration with Biogen (BIIB - Free Report) .
Image: Bigstock
Denali (DNLI) Stock Up Despite Wider-Than-Expected Q3 Loss
Denali Therapeutics’ (DNLI - Free Report) shares rose 4.4% on Nov 5, after the company reported third-quarter results and positive pipeline updates.
Denali incurred a loss of 69 cents per share for third-quarter 2021, wider than the Zacks Consensus Estimate of a loss of 51 cents and the year-ago loss of 54 cents, primarily due to higher expenses and lower revenues.
Collaboration revenues came in at $5.3 million for the reported quarter, missing the Zacks Consensus Estimate of $25 million and declining from $9.4 million in the year-ago period. The year-over-year decline was primarily owing to a decrease in revenues from the company’s collaboration with Takeda (TAK - Free Report) , driven by a decrease in costs incurred in the partnered programs.
In the year so far, Denali’s shares have declined 34.3% compared with the industry’s 12.4% decline.
Quarter in Detail
Research and development expenses were $71.6 million for the quarter under review compared with $53.7 million in the year-ago period, primarily driven by an increase in personnel-related costs.
General and administrative expenses were $19.3 million, up from $15.8 million in the year-ago quarter due to an increase in personnel-related costs, including stock-based compensation, primarily due to higher headcount and additional equity award grants.
Cash, cash equivalents and marketable securities were approximately $1.4 billion as of Sep 30, 2021.
Recent Updates
In September, the company announced that it initiated dosing participants in a phase Ib study with DNL343, its brain-penetrant small molecule activator of EIF2B, in amyotrophic lateral sclerosis (ALS) patients. Denali initiated the study on the basis of positive data from preclinical and phase I studies, wherein DNL343 achieved safety and biomarker goals.
Denali also announced additional positive interim data from a phase I/II study evaluating ETV:IDS (DNL310), an investigational brain-penetrant enzyme replacement therapy intended to treat both central nervous system and peripheral manifestations of Hunter syndrome in July 2021. Based on this data, the company will initiate a pivotal phase II/III study in first-half 2022 and is currently enrolling patients in Cohort C of the phase I/II study to further evaluate the clinical endpoints of the study in patients aged below four years in Hunter syndrome.
Last month, Denali announced that partner Sanofi (SNY - Free Report) plans to initiate a phase II HIMALAYA study in first-quarter 2022 to evaluate the efficacy and safety of RIPK1 inhibitor, DNL788, in adult patients having ALS.
The company also plans to initiate late-stage clinical development of its LRRK2 inhibitor, DNL151, in Parkinson's disease. DNL151 is being developed in collaboration with Biogen (BIIB - Free Report) .
Denali Therapeutics Inc. Price
Denali Therapeutics Inc. price | Denali Therapeutics Inc. Quote
Zacks Rank
Denali currently has a Zacks Rank #5 (Strong Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.